ATE49125T1 - Pharmazeutische zusammensetzungen mit gehalt an insulin. - Google Patents

Pharmazeutische zusammensetzungen mit gehalt an insulin.

Info

Publication number
ATE49125T1
ATE49125T1 AT84401049T AT84401049T ATE49125T1 AT E49125 T1 ATE49125 T1 AT E49125T1 AT 84401049 T AT84401049 T AT 84401049T AT 84401049 T AT84401049 T AT 84401049T AT E49125 T1 ATE49125 T1 AT E49125T1
Authority
AT
Austria
Prior art keywords
acid
insulin
pharmaceutical compositions
compositions containing
containing insulin
Prior art date
Application number
AT84401049T
Other languages
English (en)
Inventor
Miriam Kidron
Ehud Ziv
Hanoch Bar-On
Amiram Eldor
Original Assignee
Hadassah Med Org
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadassah Med Org filed Critical Hadassah Med Org
Application granted granted Critical
Publication of ATE49125T1 publication Critical patent/ATE49125T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT84401049T 1983-05-23 1984-05-21 Pharmazeutische zusammensetzungen mit gehalt an insulin. ATE49125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL68769A IL68769A (en) 1983-05-23 1983-05-23 Pharmaceutical compositions containing insulin for oral administration
EP84401049A EP0127535B1 (de) 1983-05-23 1984-05-21 Pharmazeutische Zusammensetzungen mit Gehalt an Insulin

Publications (1)

Publication Number Publication Date
ATE49125T1 true ATE49125T1 (de) 1990-01-15

Family

ID=11054289

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84401049T ATE49125T1 (de) 1983-05-23 1984-05-21 Pharmazeutische zusammensetzungen mit gehalt an insulin.

Country Status (8)

Country Link
US (1) US4579730A (de)
EP (1) EP0127535B1 (de)
JP (1) JPH0678238B2 (de)
AT (1) ATE49125T1 (de)
CA (1) CA1223200A (de)
DE (1) DE3480903D1 (de)
DK (1) DK167240B1 (de)
IL (1) IL68769A (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
GB8417895D0 (en) * 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
WO1987005505A1 (en) * 1986-03-21 1987-09-24 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
JP2586476B2 (ja) * 1987-03-10 1997-02-26 藤森工業株式会社 脱気用部材
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US20040115217A1 (en) * 1987-06-24 2004-06-17 Autolmmune Inc. Bystander suppression of autoimmune diseases
CA1338824C (en) * 1987-08-07 1996-12-31 Protor Co. Hypoglycemic and growth-promoting agent isolated from bacitracin
FR2619717B1 (fr) * 1987-09-02 1991-07-12 Medibrevex Nouvelles formes galeniques d'insuline pour administration par voie per- et sublinguale
DE3887494T2 (de) * 1987-11-13 1994-05-19 Smithkline Beecham Farma Ein Calcitonin sowie ein Glycyrrhizinat als Absorptionsförderer enthaltende Arzneimittel.
JP2756787B2 (ja) * 1988-04-30 1998-05-25 日東電工株式会社 水溶性生理活性蛋白質製剤
US5275819A (en) * 1989-02-06 1994-01-04 Amer Particle Technologies Inc. Drug loaded pollen grains with an outer coating for pulsed delivery
JPH02250823A (ja) * 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
US6156731A (en) * 1989-05-10 2000-12-05 G. D. Searle & Co. Polypeptide composition for oral administration
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5079240A (en) * 1990-03-15 1992-01-07 The Regents Of The University Of California Synthetic conjugated bile acid and method of use thereof
GB9013448D0 (en) * 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
FR2668933B1 (fr) * 1990-06-15 1995-05-05 Sandoz Sa Composition pharmaceutique a base de somatostatine.
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
EP0533938A4 (en) * 1991-02-19 1993-06-16 Tsumura & Co. Composition for rectal administration of difficultly absorbable peptide
IT1245889B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
AU3058392A (en) * 1991-12-18 1993-07-19 Pfizer Inc. Soybean protein or hydrolyzates in pharmaceutical compositions to protect bioactive peptides from enzymatic inactivation
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US6153592A (en) * 1992-11-09 2000-11-28 Port Systems, Llc Enhancing the bioavailability of proteolytically labile therapeutic agents
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
AU7273494A (en) * 1993-09-01 1995-03-22 Pfizer Inc. Pharmaceutical compositions containing anionic surfactants
PT792290E (pt) * 1993-09-17 2002-01-30 Novo Nordisk As Insulina acilada
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
RU2066551C1 (ru) * 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Способ получения инсулинсодержащих полимерных гидрогелей
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
IL114673A (en) * 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
AU1808897A (en) * 1995-12-13 1997-07-03 Dullatur Limited A calcitonin preparation
US5846525A (en) * 1995-12-19 1998-12-08 Trega Biosciences, Inc. Protected biopolymers for oral administration and methods of using same
EP0943336A1 (de) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptid-enthaltende Wirkstoffzusammensetzungen zur oralen Verabreichung
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
GB2355009A (en) * 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
RU2155602C1 (ru) * 1999-11-30 2000-09-10 Оао "Куантум Сатис" Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
CN1406131A (zh) * 2000-12-25 2003-03-26 株式会社资生堂 活化交感神经的香料组合物
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
JP2004167178A (ja) * 2002-11-15 2004-06-17 Masashi Takahashi タン白質の経口投与法
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20080279843A1 (en) * 2003-12-09 2008-11-13 Essential Skincare, Llc Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
JP2007535546A (ja) * 2004-04-29 2007-12-06 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 代謝性骨疾患を処置するための骨形成タンパク質を含む経口製剤
US7605123B2 (en) 2004-07-19 2009-10-20 Biocon Ltd. Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof
JP4524229B2 (ja) * 2005-09-01 2010-08-11 矢崎総業株式会社 電装モジュール及び電装ユニット
US9259456B2 (en) * 2005-09-06 2016-02-16 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
JP4860700B2 (ja) 2005-09-20 2012-01-25 シェーリング コーポレイション ヒスタミンＨ３アンタゴニストとして有用な、１−［［１−［（２−アミノ−６−メチル−４−ピリジニル）メチル］−４−フルオロ−４−ピペリジニル］カルボニル］−４−［２−（２−ピリジニル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−３−イル］ピペリジン
MX2008004674A (es) * 2005-10-13 2008-11-12 Biocon Ltd Proceso para la preparacion de conjugados de insulina.
AU2007230989A1 (en) * 2006-03-22 2007-10-04 President And Fellows Of Harvard College Methods and compositions for treating hypercholesterolemia and atherosclerosis
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
JP2011500727A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
AU2009230718B2 (en) * 2008-03-26 2013-07-11 Oramed Ltd. Methods and compositions for oral administration of proteins
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
NO2300031T3 (de) * 2008-05-05 2018-02-17
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
US20110166124A1 (en) 2008-07-23 2011-07-07 Mccormick Kevin D Tricyclic spirocycle derivatives and methods of use
ES2823233T3 (es) * 2008-08-18 2021-05-06 Entera Bio Ltd Métodos y composiciones para la administración oral de proteínas
GB0817969D0 (en) * 2008-10-01 2008-11-05 Axcess Ltd Pharmaceutical composition
EP2350020B1 (de) 2008-10-03 2014-08-13 Merck Sharp & Dohme Corp. Spiro-imidazolonderivate als glucagonrezeptorantagonisten
JP2012505899A (ja) 2008-10-16 2012-03-08 シェーリング コーポレイション アジン誘導体およびそれの使用方法
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
WO2010071822A1 (en) 2008-12-19 2010-06-24 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
EP2382203B1 (de) 2008-12-23 2015-01-14 Merck Sharp & Dohme Corp. Bicyclische heterozyklusderivate und verfahren zu deren anwendung
JP2012513469A (ja) 2008-12-23 2012-06-14 シェーリング コーポレイション ピリミジン誘導体及びその使用法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AU2010212794A1 (en) 2009-02-12 2011-08-11 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin- 1 for the treatment of metabolic diseases
EP2408766A1 (de) 2009-03-18 2012-01-25 Schering Corporation Bicyclische verbindungen als inhibitoren von diacylglycerinacyltransferase
WO2010111466A1 (en) 2009-03-27 2010-09-30 The Trustees Of Columbia University In The City Of New York Aptamer-mediated drug release
EP2414348B1 (de) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclische piperidin- und piperazinderivate als gpcr-modulatoren zur behandlung von obesitas, diabetes und anderen stoffwechselkrankheiten
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EP2440553B1 (de) 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophene als glucagonrezeptorantagonisten, zusammensetzungen und verfahren zu ihrer verwendung
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
US20120172369A1 (en) 2009-09-14 2012-07-05 Ting Pauline C Inhibitors of diacylglycerol acyltransferase
WO2011043994A1 (en) 2009-10-08 2011-04-14 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
EP2493307B1 (de) 2009-10-29 2016-04-27 Merck Sharp & Dohme Corp. Verbrückte bizyklische pyrimidinderivate und verwendungsverfahren dafür
EP2503891B1 (de) 2009-11-23 2016-08-03 Merck Sharp & Dohme Corp. Pyrimidin-ether-derivate und verwendungsverfahren dafür
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
WO2011066137A1 (en) 2009-11-24 2011-06-03 Schering Corporation Substituted biaryl derivatives and methods of use thereof
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP3260131A1 (de) 2012-01-03 2017-12-27 Oramed Ltd. Kapseln enthaltend ölige flüssige zusammensetzungen von kombinierten therapeutischen wirkstoffen zur behandlung von diabetes
ES2912138T3 (es) 2012-02-01 2022-05-24 Oramed Ltd Composiciones que contienen inhibidores de proteasa, composiciones que comprenden las mismas y métodos para producir y usar las misma
WO2014057522A1 (en) 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014106846A2 (en) 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968245B1 (de) 2013-03-15 2021-05-05 Mochida Pharmaceutical Co., Ltd. Zusammensetzungen und verfahren zur behandlung nichtalkoholischer steatohepatitis
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JP7164950B2 (ja) 2014-10-31 2022-11-02 ユニバーシティー オブ ユタ リサーチ ファウンデーション 胆汁酸粒子の組成物及び方法
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP3544614A4 (de) 2016-11-28 2020-08-05 Lipocine Inc. Orale testosteron-undecanoat-therapie
CN109498559B (zh) * 2018-11-30 2022-04-12 复旦大学 一种负载糖尿病治疗多肽的口服制剂及其制备方法
WO2023017537A1 (en) 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
JPS5257313A (en) * 1975-11-07 1977-05-11 Yamanouchi Pharmaceut Co Ltd Manufacture of micellar insuline emulsion preparations
DE2640707C3 (de) * 1976-09-10 1980-01-24 Karl Dr.Med. 7302 Ostfildern Theurer Verfahren zur Herstellung von Arzneipräparaten mit einem Gehalt an von im Darm resorbierbaren Protein und Peptidlösungen
JPS5940137B2 (ja) * 1976-10-14 1984-09-28 武田薬品工業株式会社 経口投与用医薬組成物
JPS5821622A (ja) * 1981-07-28 1983-02-08 Kowa Co 糖尿病治療用薬剤
EP0071433A1 (de) * 1981-07-28 1983-02-09 Kowa Company, Ltd. Arzneimittel zur Behandlung von Diabetes
FR2515960A1 (fr) * 1981-11-06 1983-05-13 Alkhouri Fallouh Nazir Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration

Also Published As

Publication number Publication date
EP0127535A2 (de) 1984-12-05
IL68769A0 (en) 1983-09-30
DE3480903D1 (de) 1990-02-08
DK229484D0 (da) 1984-05-09
EP0127535A3 (en) 1987-01-14
DK229484A (da) 1984-11-24
DK167240B1 (da) 1993-09-27
EP0127535B1 (de) 1990-01-03
CA1223200A (en) 1987-06-23
IL68769A (en) 1986-02-28
JPS6069028A (ja) 1985-04-19
US4579730A (en) 1986-04-01
JPH0678238B2 (ja) 1994-10-05

Similar Documents

Publication Publication Date Title
ATE49125T1 (de) Pharmazeutische zusammensetzungen mit gehalt an insulin.
MY102459A (en) Oral sustained release pharmaceutical preparation.
DK0843558T3 (da) Sammensætning til forstærket optagelse af polære lægemidler fra colon
ATE401892T1 (de) Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand
IL67572A (en) Trans-2-aza bicyclo(3.(3+n).o)alkane-3-carboxylic acid derivatives,processes for their preparation and pharmaceutical compositions containing them
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
DE69212879D1 (de) Magensaftstabile pharmazeutische Formulierungen zur Oral Verbreichung von Gallensäuren
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
TR200001977T2 (tr) Lipofilik glukokortikosteroit içeren miseller ihtiva eden bileşimler
IL52127A0 (en) Novel phosphonous acid derivatives their preparation and pharmaceutical compositions containing them
PL309777A1 (en) Novel ileum and colon specific steroid derivatives
HUP9801414A2 (hu) Nátrium-alginátot és kálium-bikarbonátot tartalmazó folyékony vizes gyógyszerkészítmények
DK62187D0 (da) Farmaceutisk praeparat indeholdende 3alfa-hydroxy-5beta-pregnan-20-on og fremstilling deraf
DK0514328T3 (da) Chenodeoxycholsyre eller ursodeoxycholsyre til behandling af sygdomme i åndedrætsorganerne
ZA93727B (en) New parathormone fragments, process for the preparation thereof and pharmaceutical compositions containing them.
NZ184593A (en) Phosphonic acid derivatives of certain peptides and pharmaceutical compositions containing them
AU1879597A (en) Tetraether lipids and liposomes containing said lipids, and use of the same
NZ184653A (en) Phosphonic acid peptide derivatives and pharmaceutical compositions containing them
ATE86965T1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
GB1459485A (en) Medicament pack for the oral treatment with oestrogen
SE8700157D0 (sv) Sett att forhindra kvicksilverforgiftning orsakad av upplosning av kvicksilver ur amalgamplomber samt komposition herfor
JPS55120756A (en) Feed for domestic fowl
ATE34382T1 (de) Substituierte dipeptide, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zusammensetzungen und verfahren zur herstellung dieser pharmazeutischen zusammensetzungen.
IT1254688B (it) Composizioni farmaceutiche somministrabili per via orale a rilascio mirato contenenti acido ursodesossicolico ed acido chenodesossicolico.
ES8600889A1 (es) Procedimiento para preparar composiciones edulcorantes a base de dipeptidos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee